Emerging cell types are broadening the treatment scope of cell therapy, while automation, PAT and strategic partnerships are addressing manufacturing challenges. Emphasizing the safety of these therapies will improve accessibility and build patient trust, ultimately enhancing the impact of CAR-T ...
The cutting edge of cancer research is now expanding beyond conventional T cells to a less-explored, unconventional, unique subset of T cell: mucosal-associated invariant T (MAIT) cells. Engineered MAIT cells may stand to change future allogeneic treatments for solid tumors.
Against a backdrop of historic charm, bold visions for the future of medicine were exchanged as attendees from all over the globe showed up in force to learn, present, collaborate and reconnect on all aspects of cell and gene therapies.
ISCT is an important event for meeting leaders in the field of cell therapy, exploring the biggest challenges and bottlenecks, and mapping out potential solutions.
ASGCT is an important meeting to get a lay-of-the-land for the research and early-stage progress for the field of gene therapy, and to help identify the key trends going into the next decade of development for advanced therapies.
Advances in interactive response technology platforms for drug supply can be highly beneficial when thoughtfully designed to address the unique challenges of CGT trials. This is especially true when these platforms are integrated into a comprehensive consultative approach led by specialized ...
As the CGT space grows, making therapies available to more patients will require an all-encompassing approach to improving efficiency to lower manufacturing costs. New seed train technologies can not only improve viral vector manufacturing but has applications for other types of adherent production ...
Patient-specific therapies come with unique logistics that bring added complexity and risk to supply chains. Manufacturing these therapies will continue to require robust supply chain management, stringent quality control and specialized components throughout the network — from facilities and ...
Much of the focus for making CGTs accessible and commercially viable has looked downstream at manufacturing, logistics, geography, centralization, and even intellectual property. However, the vast majority of ex vivo advanced therapies share the same starting point — blood — and the future of CGT ...
While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift cell therapies to new heights, but it could redefine them entirely.